Prof. Winnie Yeo
楊明明教授
Specific Research / Sites of Interest
• Breast and gynecological cancers• Gastric cancer and HBV-related oncological issues
• Symptom management and cancer survivorship
Short Biography
Professor Winnie Yeo graduated from King’s College Hospital, University of London. She underwent postgraduate training in Addenbrooke’s Hospital, Cambridge, and at King’s College, Westminster and Royal Marsden Hospitals in London before returning to Hong Kong. Professor Yeo is currently Professor of the Department of Clinical Oncology, Faculty of Medicine, the Chinese University of Hong Kong and Chief of Service in the Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong. She is the Co-Director of the Comprehensive Cancer Trials Unit of the Department of Clinical Oncology, the Chinese University of Hong Kong. She was the Chairman of the Medical Oncology Specialty of the Hong Kong College of Physicians between 2007 and 2013, and Immediate Past President of the Hong Kong Breast Oncology Group. She serves as a member and advisor in various expert panels and committees within the University, the Hong Kong Hospital Authority and various health advisory panels. She has authored and coauthored over 270 papers including Journal of the National Cancer Institute, Lancet, Lancet Oncology, Journal of Clinical Oncology, Hepatology etc. Her main research interests are management of breast, gynecological and gastric cancer patients.Most Representative Publications
1. Yeo W, Lau TKH, Kwok CCH, Lai KT, Chan VTC, Li L, Chan V, Wong A, Soo WMT, Yeung EWM, Wong KH, Tang NLS, Suen JJS, Mo FKF. NEPA efficacy and tolerability during (neo) adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin. BMJ Support Palliat Care. 2022;12(e2):e264-70. |
2. Yeo W, Lau TKH, Li L, Lai KT, Pang E, Cheung M, Chan VTC, Wong A, Soo WMT, Yeung VTY, Tse T, Lam DCM, Yeung EWM, Ng KPK, Tang NLS, Tong M, Suen JJS, Mo FKF. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. Breast. 2020;50:30-8. |
3. Lei YY, Ho SC, Cheng A, Kwok C, Cheung KL, He YQ, Lee R, Yeo W. The association between soy isoflavone intake and menopausal symptoms after breast cancer diagnosis: a prospective longitudinal cohort study on Chinese breast cancer patients. Breast Cancer Res Treat. 2020 May;181(1):167-180. |
4. Yeo W, Pang E, Liem GS, Suen JJS, Ng RYW, Yip CCH, Li L, Yip CHW, Mo FKF. Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors. Health Qual Life Outcomes. 2020;18(1):1-9. |
5. Yeo W, Ueno T, Lin CH, Liu Q, Lee KH, Leung R, Naito Y, Park YH, Im SA, Li H, Yap YS, Lu YS, The Asian Breast Cancer Cooperative Group. Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Res Treat. 2019;177(3):549-59. |
6. W Yeo, Chan SL, Mo FKF, et al. Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012, 30(27): 3361-67. |
7. W Yeo, TC Chan, NWY Leung, et al. Hepatitis B Virus Reactivation in Lymphoma Patients with History of resolved Hepatitis B Being Treated with or without Rituximab-containing Anti-cancer Therapy. J Clin Oncol 2009, 27(4): 605-611. |
8. W Yeo, et al. Hepatitis B Viral Load Predicts Survival of Patients with Hepatocellular Carcinoma (HCC) Undergoing Systemic Chemotherapy. Hepatology 2007, 45(6): 1382-1389. |
9. W Yeo, PJ Johnson. Diagnosis, prevention and management of hepatitis B virus reactivation during anti-cancer therapy. Hepatology 2006, 43(2): 209-220. |
10. W Yeo, et al. Phase III study of adriamycin versus cisplatin/interferon a-2b/adriamycin/fluorouracil combination chemotherapy for inoperable hepatocellular carcinoma. J Natl Cancer Inst 2005, 97(20): 1532-1538. |